Mankind Pharma Sees Sharp Open Interest Surge Amid Sustained Gains and Elevated Volume

Open Interest and Volume Dynamics

The latest data reveals that Mankind Pharma’s open interest (OI) in derivatives rose sharply by 3,242 contracts, a 13.95% increase from the previous figure of 23,247 to 26,489. This rise in OI is accompanied by a substantial volume of 38,946 contracts traded, indicating heightened activity and fresh positions being established by market participants.

In monetary terms, the futures segment alone accounted for a value of approximately ₹11,106.5 lakhs, while the options segment’s value stood at an impressive ₹21,817.3 crores, culminating in a total derivatives value of ₹13,803.8 lakhs. Such figures underscore the significant liquidity and interest in Mankind Pharma’s derivatives, making it a focal point for traders and investors alike.

Price Performance and Market Positioning

Despite the surge in derivatives activity, Mankind Pharma’s stock price underperformed its sector by 0.7% on the day, closing with a modest gain of 0.42%. However, the stock has demonstrated resilience with a consecutive five-day gain, delivering an 8.49% return over this period. The stock’s intraday high touched ₹2,604, marking a 2.59% increase from its previous close.

Technically, Mankind Pharma is trading above all key moving averages – 5-day, 20-day, 50-day, 100-day, and 200-day – signalling a robust upward trend. This technical strength is further supported by rising investor participation, with delivery volumes on 22 June reaching 4.54 lakh shares, a remarkable 110.27% increase compared to the five-day average delivery volume. Such elevated delivery volumes suggest genuine accumulation rather than speculative trading.

Market Capitalisation and Sector Context

With a market capitalisation of ₹1,07,032 crores, Mankind Pharma is classified as a mid-cap stock within the Pharmaceuticals & Biotechnology sector. The sector itself has been performing well, with a 1.19% gain on the day, outpacing the Sensex which declined marginally by 0.09%. Mankind Pharma’s relative underperformance on the day may be a short-term phenomenon, given its strong technicals and positive momentum over the past week.

Interpreting the Open Interest Surge

The 13.95% increase in open interest, coupled with rising volumes, suggests that new positions are being built rather than existing ones being squared off. This typically indicates a strong conviction among traders about the stock’s future direction. Given the stock’s upward price trend and technical strength, it is plausible that the majority of these positions are bullish bets, anticipating further appreciation.

Moreover, the substantial value in options contracts points to active hedging and speculative strategies. The large notional value in options could imply that traders are positioning for volatility or directional moves, possibly leveraging call options to benefit from upside potential or protective puts to manage risk.

Investor Sentiment and Quality Assessment

Mankind Pharma’s Mojo Grade was upgraded from Hold to Buy on 18 June 2026, reflecting improved fundamentals and market sentiment. The current Mojo Score of 72.0 places it favourably among mid-cap pharmaceuticals stocks, signalling a strong buy recommendation based on a comprehensive analysis of financial metrics, price trends, and sector positioning.

Liquidity remains adequate for sizeable trades, with the stock’s average traded value supporting trade sizes up to ₹2.47 crores based on 2% of the five-day average traded value. This ensures that institutional investors can enter or exit positions without significant market impact, further enhancing the stock’s appeal.

Potential Directional Bets and Outlook

The combination of rising open interest, increasing volumes, and positive price momentum suggests that market participants are positioning for further gains in Mankind Pharma. The stock’s consistent outperformance over the last five sessions, supported by strong technical indicators, reinforces this bullish outlook.

However, investors should remain mindful of sector volatility and broader market conditions. While the pharmaceutical sector is generally defensive, regulatory developments and competitive pressures can influence stock performance. The current derivatives activity may also reflect hedging strategies that could temper upside in the near term.

Overall, the data points to a constructive market stance on Mankind Pharma, with increased investor participation and confidence. The stock’s upgraded Mojo Grade and solid fundamentals provide a strong foundation for continued appreciation, making it an attractive proposition for mid-cap investors seeking exposure to the Pharmaceuticals & Biotechnology sector.

Summary

Mankind Pharma Ltd’s recent surge in open interest and trading volumes in derivatives highlights growing market interest and potential bullish positioning. The stock’s technical strength, rising delivery volumes, and upgraded Mojo Grade underpin a positive outlook despite a slight short-term underperformance relative to its sector. Investors should consider the stock’s liquidity, sector dynamics, and ongoing momentum when evaluating their exposure to this mid-cap pharmaceutical player.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →